Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Summit Therapeutics Inc. (SMMT)

Summit Therapeutics files prospectus supplement and legal opinion on share issuance

Neutral Impact 2 of 5 financing Written later

Summit Therapeutics filed a prospectus supplement under its automatic shelf registration statement on Form S-3 and an accompanying 8-K to file a legal opinion from Baker & Hostetler LLP on the legality of the common stock issuance. The filing does not state the number of shares, the price, or the amount of proceeds, so the filing alone does not show the size or dilution effect of the offering.

Key points

  • Prospectus supplement filed November 4, 2026 under Form S-3 (Registration No. 333-296642)
  • Baker & Hostetler LLP legality opinion filed as Exhibit 5.1, with consent as Exhibit 23.1
  • Filing does not disclose share count, offering price, or proceeds

The filing

CompanySummit Therapeutics Inc. (SMMT)
Form8-K, current report
Filed with the SECNov 4, 2026, 5:22 PM ET
Accession number0001193125-26-447661

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.